RT Journal Article
SR Electronic
T1 Comparing surveyed adults with long COVID and those with just a positive test helps put COVID into perspective
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.02.24302216
DO 10.1101/2024.02.02.24302216
A1 Adams, Mary L.
A1 Grandpre, Joseph
YR 2024
UL http://medrxiv.org/content/early/2024/02/03/2024.02.02.24302216.abstract
AB Introduction Among adults who test positive for COVID-19, some develop long COVID (symptoms lasting ≥3 months), and some do not. We compared 3 groups on selected measures to help determine strategies to reduce COVID impact.Methods Using Stata and data for 385,617 adults from the 2022 Behavioral Risk Factor Surveillance System, we compared adults reporting long COVID, those with just a positive test, and those who never tested positive, on several health status and risk factor measures plus vaccination rates (data for 178,949 adults in 29 states).Results Prevalence of just COVID was 26.5% (95% CI 26.2-26.8) and long COVID was 7.4% (7.3-7.6). Compared with adults with just COVID those with long COVID had worse rates for 13 of 17 measures of chronic disease, disability, and poor health status, while those with just COVID had the best results for 15 of the 17 measures among all 3 groups. The 5 risk factors (obesity, diabetes, asthma, cardiovascular disease, and COPD) previously associated with COVID deaths, increased long COVID but not just COVID rates, which were highest among younger and higher income adults. Adults with long COVID had the highest rate among the 3 groups for any COVID risk factors and data from 29 states showed they had the lowest rates for ≥3 vaccine doses of 35.6%, vs. 42.7% and 50.3% for those with just a positive test, and neither, respectively. Vaccination with ≥3 vaccines vs. <3 reduced long COVID rates by 38%, and just COVID rates by 16%.Conclusions Results show the seriousness of long COVID vs. just a positive test and that increasing vaccine coverage by targeting adults with risk factors shows promise for reducing COVID impact.Competing Interest StatementThe authors have declared no competing interest.Funding StatementStudy partially supported by a cooperative agreement from CDC (#1NU58DP006901)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data are publicly available from CDC with website and link listed in references. https://www.cdc.gov/brfss/annual_data/annual_2022.html.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used are available at https://www.cdc.gov/brfss/annual_data/annual_2022.html.https://www.cdc.gov/brfss/annual_data/annual_2022.html.